These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 12707994)
1. [Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease]. Kamijo A; Sugaya T; Hikawa A; Kimura K Rinsho Byori; 2003 Mar; 51(3):219-24. PubMed ID: 12707994 [TBL] [Abstract][Full Text] [Related]
2. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. Kamijo A; Kimura K; Sugaya T; Yamanouchi M; Hikawa A; Hirano N; Hirata Y; Goto A; Omata M J Lab Clin Med; 2004 Jan; 143(1):23-30. PubMed ID: 14749682 [TBL] [Abstract][Full Text] [Related]
3. Influence of renal function on serum and urinary heart fatty acid-binding protein levels. Nayashida N; Chihara S; Tayama E; Akasu K; Kai E; Kawara T; Aoyagi S J Cardiovasc Surg (Torino); 2001 Dec; 42(6):735-40. PubMed ID: 11698938 [TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Kimura K J Lab Clin Med; 2005 Mar; 145(3):125-33. PubMed ID: 15871303 [TBL] [Abstract][Full Text] [Related]
5. [L-type fatty acid binding protein (L-FABP) and kidney disease]. Kamijo-Ikemori A; Sugaya T; Kimura K Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492 [TBL] [Abstract][Full Text] [Related]
6. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan]. Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707 [TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of liver fatty acid-binding protein in health-check participants. Ishimitsu T; Ohta S; Saito M; Teranishi M; Inada H; Yoshii M; Minami J; Ono H; Hikawa A; Shibata N; Sugaya T; Kamijo A; Kimura K; Ohrui M; Matsuoka H Clin Exp Nephrol; 2005 Mar; 9(1):34-9. PubMed ID: 15830271 [TBL] [Abstract][Full Text] [Related]
18. Ablation of the liver fatty acid binding protein gene decreases fatty acyl CoA binding capacity and alters fatty acyl CoA pool distribution in mouse liver. Martin GG; Huang H; Atshaves BP; Binas B; Schroeder F Biochemistry; 2003 Oct; 42(39):11520-32. PubMed ID: 14516204 [TBL] [Abstract][Full Text] [Related]
19. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis. Mou S; Wang Q; Li J; Shi B; Ni Z Clin Chim Acta; 2012 Jan; 413(1-2):187-91. PubMed ID: 21958699 [TBL] [Abstract][Full Text] [Related]
20. Effect of habitual exercise on urinary liver-type fatty acid-binding protein levels in middle-aged and older adults. Kosaki K; Kamijo-Ikemori A; Sugaya T; Tanahashi K; Sawano Y; Akazawa N; Ra SG; Kimura K; Shibagaki Y; Maeda S Scand J Med Sci Sports; 2018 Jan; 28(1):152-160. PubMed ID: 28247579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]